Press-release for stocks for lly

Prices are updated after-hours

Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

symbols : Lly crawled time : 14:30

save search

Monoclonal Antibody (mABs) Therapeutics Market Worth $497.5 billion | MarketsandMarkets™
Published: 2024-03-15 (Crawled : 14:30) - prnewswire.com
TAK | News | $13.23 -1.12% 0.0% 920K

|

Health Technology

| -6.94% | O: 0.21% H: 0.97% C: 0.7%
NVS | News | $98.35 1.1% 0.0% 2.2M

|

Health Technology

| 0.74% | O: 0.05% H: 0.14% C: -0.93%
JNJ | News | $148.53 -0.69% -0.14% 9.6M

|

Health Technology

| -6.92% | O: -1.58% H: 0.0% C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| -2.85% | O: -0.7% H: 0.73% C: -0.16%
ABBV | News | $167.8 -1.03% -0.06% 4.1M

|

Health Technology

| -5.97% | O: -0.07% H: 0.0% C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M

|

Health Technology

| -2.83% | O: -0.02% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

|

Health Technology

| -5.39% | O: -0.27% H: 1.26% C: 0.84%
AMGN | News | $273.085 -0.17% -0.17% 2.5M

|

Health Technology

| 0.74% | O: 0.2% H: 1.14% C: -1.18%
antibody therapeutics market

Amylyx Pharmaceuticals Appoints Bernhardt Zeiher, MD, FCCP, FACP, to its Board of Directors
Published: 2024-03-14 (Crawled : 14:30) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

|

| -43.31% | O: -1.45% H: 0.04% C: -6.49%
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| -2.48% | O: 0.94% H: 0.4% C: -0.55%
pharmaceuticals

Philip Johnson to Retire as Lilly Treasurer
Published: 2024-02-09 (Crawled : 14:30) - prnewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 0.46% | O: -0.02% H: 1.39% C: 0.63%

FDA Roundup: December 5, 2023
Published: 2023-12-05 (Crawled : 14:30) - fda.gov
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 26.79% | O: 0.99% H: 0.0% C: 0.0%
fda

Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 15, 2023
Published: 2023-12-04 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 24.42% | O: -1.96% H: 0.0% C: 0.0%
biopharma acquire

The Top 12 Biopharma Companies Hiring Now
Published: 2023-09-13 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 23.32% | O: -0.77% H: 0.0% C: 0.0%
companies biopharma

Sermonix Pharmaceuticals Shares Encore ELAINE-2 Poster Presentation at 2023 Metastatic Breast Cancer Research Conference
Published: 2023-09-05 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 33.06% | O: 0.68% H: 0.48% C: -0.19%
LGND | $70.87 1.4% 1.38% 150K

|

Health Technology

| 5.03% | O: -0.86% H: 0.0% C: -3.7%
conference breast presentation cancer pharmaceuticals research

Entos Pharmaceuticals Announces Senior Leadership Appointments to Expand Executive Team and Accelerate Growth
Published: 2022-03-03 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 196.05% | O: 2.08% H: 1.86% C: 1.5%
LJPC | $6.22 0.0%

|

Health Technology

| 47.51% | O: 1.9% H: 1.63% C: -2.33%
als ces cel growth

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline
Published: 2022-03-01 (Crawled : 14:30) - ir.pulmatrix.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 202.13% | O: 1.26% H: 0.0% C: 0.0%
PULM | $2.0201 2.0% 4.1K

|

Health Technology

| 554.36% | O: 1843.63% H: 2.17% C: -4.67%
matrix expansion

Lilly Pumps $700M into Boston-Based RNA Therapeutics Facility
Published: 2022-02-22 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 207.54% | O: -0.46% H: 0.69% C: -0.03%
therapeutics

Veru Announces the Presentation of Updated Data from the Phase 1b/2 Sabizabulin Study in Men with Metastatic Castration Resistant Prostate Cancer at the 2022 ASCO Genitourinary Cancers Symposium
Published: 2022-02-17 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 200.94% | O: 0.0% H: 0.0% C: -1.88%
VERU | $1.325 3.92% 3.77% 1.5M

|

Health Technology

| -79.78% | O: -0.96% H: 0.88% C: -3.38%
prostate cancer symposium state phase 1b presentation asco phase 1 cancer sabizabulin phase 2b

Veru Reports that Independent Data Monitoring Committee for the Phase 3 Sabizabulin COVID-19 Clinical Study Recommends Continuing Study as Planned
Published: 2022-02-14 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 208.58% | O: -2.3% H: 1.23% C: 0.29%
VERU | $1.325 3.92% 3.77% 1.5M

|

Health Technology

| -80.03% | O: -0.47% H: 5.06% C: -4.11%
covid-19 covid report phase 3 sabizabulin

180 Degree Capital Corp. Portfolio Company, D-Wave Systems, Inc., Announces Intent to Become a Public Company Through a Merger With DPCM Capital, Inc. and Provides an Update on Legacy Private Portfolio Monetization Efforts
Published: 2022-02-08 (Crawled : 14:30) - globenewswire.com
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 204.15% | O: -0.45% H: 0.0% C: 0.0%
TURN | $3.94 -0.25% 10K

|

| -45.28% | O: 0.97% H: 8.67% C: 5.98%
ces system one merge

Veru Enters into Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate Enobosarm in Combination with Verzenio® in Phase 3 ENABLAR-2 Trial
Published: 2022-02-01 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 203.16% | O: 1.37% H: 0.0% C: 0.0%
VERU | $1.325 3.92% 3.77% 1.5M

|

Health Technology

| -75.58% | O: 2.21% H: 4.99% C: 4.05%
verzenio trial collaboration phase 3

NCCN Announces Funding for Lung and Thyroid Cancer Quality Projects, in Collaboration with Lilly
Published: 2022-01-24 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 198.69% | O: -1.97% H: 0.5% C: -0.88%
funding collaboration cancer

RION Appoints Alisa Lask as Chief Commercial Officer
Published: 2022-01-14 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 190.96% | O: -1.46% H: 0.0% C: 0.0%
NEPH | $2.19 2.34% 2.28% 7.3K

|

Health Technology

| -60.37% | O: 0.19% H: 0.0% C: -2.96%
CLGN | $5.4 0.38% 1K

|

Health Technology

| -54.89% | O: 4.18% H: 0.0% C: 0.0%
commercialization

Fostamatinib Meets Primary Endpoint in Phase 3 Trial in Japan for Treatment of Chronic Immune Thrombocytopenia
Published: 2021-12-21 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 180.5% | O: 0.2% H: 0.74% C: 0.33%
RIGL | $1.125 -1.32% -1.33% 6.4M

|

Health Technology

| -57.3% | O: 2.25% H: 0.37% C: -0.73%
treatment trial chronic immune phase 3

Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

|

Health Technology

| 204.6% | O: 1.27% H: 0.0% C: 0.0%
NKTR | News | $1.39 -2.11% -2.16% 960K

|

Health Technology

| -89.01% | O: -3.33% H: 0.0% C: 0.0%
nktr-255 ema car-t therapeutics therapy

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M

|

Consumer Services

BOF | $1.99 70.09% 41.21% 110M

|

ILAG | $0.51 6.03% 40.62% 1.7M

|

LICN | $0.941 68.04% 40.49% 15M

|

AMST | $3.31 65.5% 39.58% 70M

|

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M

|

Technology Services

WIMI | $1.15 58.53% 36.92% 19M

|

Technology Services

AIH | $0.45 12.5% 30.92% 320K

|

Health Services

MULN | News | $3.78 38.46% 27.78% 13M

|

RILY | $29.86 37.48% 27.26% 12M

|

Your saved searches

Save your searches and get alerts when important news are released.